It depends on how the dose was given, not on the drug itself. A Rocephin (ceftriaxone) dose given as a single intramuscular injection — often reconstituted with 1% lidocaine to make the volume tolerable — is 96372. The same drug run through an IV line over the labeled 30 minutes is 96365 (initial hour). Either way, the drug itself is J0696, billed at 250 mg per unit, so 1 g is J0696 × 4 and 2 g is J0696 × 8. Ceftriaxone’s label doesn’t describe an IV push method at all — if a chart documents one anyway, in 15 minutes or less, CMS’s timing definition still routes that claim to 96374, off-label administration or not.
Ceftriaxone doesn’t carry its own administration code — nothing in the 96360-96549 family is drug-specific. The code follows how the dose was actually given, the same as it would for any other therapeutic injectable. 96372 (“therapeutic, prophylactic, or diagnostic injection…intramuscular”) applies when the dose goes into muscle as a single injection, not through an IV line. 96365 is the initial hour of a therapeutic IV infusion — 16 minutes or more, with documented start and stop times. CareCost Estimate’s Rocephin reference lists exactly these two: 96365 as the drug’s initial administration code and 96372 for the injection route, which matches the two administration methods ceftriaxone’s own FDA labeling actually describes.
The label supports IM administration with a named diluent: 1% lidocaine solution, without epinephrine, is one of the reconstitution options listed for intramuscular ceftriaxone, and it is what makes a 1 g dose tolerable as a single injection instead of a painful bolus of plain sterile water. The lidocaine is a compounding diluent for the antibiotic being injected — it is not a separate therapeutic service, it carries no HCPCS line of its own, and it does not change the administration code or add a second injection code. Bill 96372 once for the injection, whatever the reconstitution vehicle was.
For IV, the label is direct about timing: ceftriaxone for injection “should be administered intravenously by infusion over a period of 30 minutes.” That is a documented administration of 16 minutes or longer — which is exactly the boundary that makes it 96365 rather than a push.
HCPCS J0696 bills at 250 mg per unit regardless of route or manufacturer. There is no brand-specific split the way some drugs have — Rocephin itself is no longer separately marketed in the US, so essentially every current claim is generic ceftriaxone billed on the same code. The unit math is direct division by 250:
| Administered dose | J0696 units |
|---|---|
| 250 mg | 1 |
| 500 mg | 2 |
| 1 g | 4 |
| 2 g | 8 |
A dose that doesn’t divide evenly into 250 mg increments rounds up to the next whole unit, never to the nearest one — Pub. 100-04 Ch. 17 §10 instructs the provider to round to the next highest unit, so a 300 mg dose bills 2 units, not 1. The Medically Unlikely Edit for J0696 is 16 units per date of service on the practitioner table (MAI 3, Date of Service Edit: Clinical) — 4 g, which lines up with ceftriaxone’s FDA-labeled adult maximum of 4 g/day. A claim above 16 units needs chart documentation to support it, not a modifier to get around the edit.
CMS defines an intravenous push by the clock: “an infusion of 15 minutes or less” (Pub. 100-04, Ch. 12 §30.5). MAC guidance extends that in practice to any IV line charted with no start and stop times at all, on the reasoning that nothing in the record supports an infusion — that documentation rule is administrative practice, not language in Chapter 12 itself. Ceftriaxone’s own labeling doesn’t describe a push method at all — the directions for use specify infusion over 30 minutes and say nothing about direct IV injection. If a chart nonetheless documents a ceftriaxone dose given IV in 15 minutes or less, CMS’s coding definition still routes that claim to 96374 on the timing alone. That is a coding outcome, stated neutrally — not an endorsement of pushing a drug faster than its own label describes. Whether that administration speed is clinically appropriate is a prescribing decision; the biller’s job is to code the minutes that were actually charted.
Some clinicians split a 2 g IM dose across two sites — left and right gluteus, commonly — because 2 g in one site is a large volume for muscle tissue to absorb comfortably. For Medicare, follow the MAC: Noridian’s Part A guidance on initial drug administration states that when a drug requires two or more syringes to be safely administered in the same session, “only one initial administration code (i.e., CPT code 96372) may be billed, regardless if two or more syringes are being used for the same drug” — one 96372 for the encounter, not one per needle stick. CPT Assistant takes the opposite position for a single ordered dose that exceeds the volume for one injection: report each injection individually with 96372, one unit per site, when both are documented. Some commercial payers follow that second position and pay 96372 ×2 with modifier 59 or XS. Follow the payer on file, and document both injection sites either way. J0696 is unaffected by either position: 2 g is 8 units on one drug line, split dose or not.
NCCI Chapter XI, Section B.8, on why 99211 disappears into the injection but higher E/M levels don’t:
“The drug and chemotherapy administration CPT codes 96360-96379 and 96401-96425 have been valued to include the work and practice expenses of CPT code 99211…Although CPT code 99211 is not reportable with chemotherapy and non-chemotherapy drug/substance administration HCPCS/CPT codes, other non-facility-based E&M CPT codes (e.g., 99202-99205, 99212-99215) are separately reportable with modifier 25 if the physician provides a significant and separately identifiable E&M service.” — NCCI Ch. XI §B.8
Applied to a Rocephin visit: a nurse-only injection encounter bills 96372 and J0696 alone — there is no E/M to add, and 99211 specifically is never separately payable with 96372 by the same provider, whatever level of nursing assessment happened around the shot. A physician visit that worked up a new complaint, adjusted an unrelated chronic condition, or made a real medical decision beyond “give the antibiotic” can add 99212-99215 with modifier 25 — on the E/M line, not on 96372. The documentation has to show a problem addressed beyond the injection itself; a visit whose entire content was the decision to give ceftriaxone does not clear that bar.
One more thing that doesn’t complicate this drug: Medicare’s Self-Administered Drug exclusion, which can strip the administration code entirely for a drug patients typically inject themselves. Ceftriaxone requires IV or IM administration by a healthcare professional; it is not a self-administered drug and does not appear on the MAC SAD exclusion lists we have checked, so the administration codes below are billable in the ordinary way — no SAD carve-out to check first.
Change the route to a 30-minute IV infusion and the administration line becomes 96365 in place of 96372; the J0696 × 4 line doesn’t change. Priced lines for either version, Medicare basis, are in the Code this visit tool on the 96365/96372 pair page.
No. Ceftriaxone administration is coded the same way any other therapeutic injectable is: 96372 for IM, 96365 (plus 96366 for additional hours) for a documented IV infusion of 16 minutes or more, or 96374 if the timing on the chart meets CMS’s push definition. J0696 is the drug’s own HCPCS code, billed separately from whichever administration code applies.
No. 1% lidocaine without epinephrine is a listed reconstitution diluent for intramuscular ceftriaxone on the manufacturer’s label. It is part of preparing the drug for injection, not a separate service, so it has no HCPCS or CPT line of its own and does not change 96372 to anything else.
No. CMS defines an IV push as “an infusion of 15 minutes or less” (Pub. 100-04, Ch. 12 §30.5), and MAC guidance treats an IV line charted with no start and stop times the same way. Ten charted minutes routes the claim to 96374, even though ceftriaxone’s FDA label only describes a 30-minute infusion and says nothing about push administration.
No. NCCI Ch. XI §B.8 states that the drug administration codes 96360-96379 and 96401-96425 have been valued to include the work and practice expenses of 99211, so it is never separately reportable with 96372 by the same provider. Other E&M levels (99212-99215) can be added with modifier 25, but only for a significant, separately identifiable problem beyond the injection.
Quoted passages are reproduced from the cited federal publications; everything else is our reading of them. The methodology by which we resolve source disagreements is described in the Methodology.